Tilray | TRLY - Ebit

Stock Price
9.44
Daily Change
-0.04 -0.42%
Monthly
-7.99%
Yearly
926.09%
Q1 Forecast
9.24

Tilray reported $-20.01M in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
Acasti Pharma USD -3.7M 1.13M Dec/2024
Akebia Therapeutics USD 13.51M 27.82M Mar/2025
Alaunos Therapeutics USD -1.19M 148K Sep/2025
Aurora Cannabis CAD -44.75M 27.14M Sep/2025
Avita Medical AUD -10.39M 1.72M Dec/2025
Canopy Growth CAD -14.3M 17.19M Sep/2025
Cronos Group USD -7.06M 62.31M Dec/2025
Dianthus Therapeutics USD -40.29M 5.36M Sep/2025
Divis Laboratories Ltd INR 7.72B 30M Dec/2025
Ionis Pharmaceuticals USD -215M 54.82M Dec/2025
IQVIA Holdings USD 2.68B 2.1B Dec/2025
Knight Therapeutics CAD 2.94M 2.4M Sep/2025
Moderna USD -857M 597M Dec/2025
Organigram Holdings CAD -28.05M 25.94M Sep/2025
Organon & Co USD 388M 28M Sep/2025
Revvity USD 145.83M 47.49M Dec/2025
Tectonic Therapeutic USD -22.33M 4.03M Jun/2025
Tilray USD -20.01M 9.34M Sep/2025
Viatris USD -157.5M 392M Dec/2025
Xeris Pharmaceuticals USD 7.89M 2.46M Sep/2025